Trial Profile
A Randomized, Partially-Blinded, Placebo-Controlled, Two-Way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs QAV 680 (Primary) ; Mometasone
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 18 Feb 2009 New trial record